ACE inhibitor | P value | ARB | P value | |
Adjusted HR (95% CI) | Adjusted HR (95% CI) | |||
White | 0.66 (0.63 to 0.70) | <0.001 | 0.56 (0.52 to 0.62) | <0.001 |
Indian | 0.74 (0.61 to 0.90) | 0.003 | 0.66 (0.52 to 0.82) | <0.001 |
Pakistani | 0.83 (0.64 to 1.09) | 0.182 | 0.78 (0.57 to 1.06) | 0.114 |
Bangladeshi | 0.97 (0.72 to 1.31) | 0.847 | 0.74 (0.49 to 1.13) | 0.164 |
Other Asian | 0.81 (0.64 to 1.03) | 0.084 | 0.96 (0.73 to 1.23) | 0.726 |
Caribbean | 1.05 (0.87 to 1.28) | 0.480 | 0.70 (0.53 to 0.92) | 0.010 |
Black African | 1.31 (1.08 to 1.59) | 0.005 | 1.24 (0.99 to 1.58) | 0.062 |
Chinese | 0.73 (0.30 to 1.79) | 0.575 | 1.53 (0.77 to 3.01) | 0.223 |
Other ethnic group | 0.82 (0.67 to 1.05) | 0.122 | 1.09 (0.86 to 1.39) | 0.475 |
HRs are comparing risks of COVID-19 in users versus non-users of ACE inhibitor and ARB, and are adjusted for age, sex, deprivation, geographical region, comorbidities (including hypertension included as a binary variable) and other medications listed in table 1.
ARB, angiotensin receptor blocker.